Akebia Therapeutics Analyst Ratings
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025
Akebia Therapeutics Announces Multiple Positive Business Updates
Investors in Akebia Therapeutics (NASDAQ:AKBA) Have Unfortunately Lost 73% Over the Last Five Years
Express News | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
